TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33874683

Group type: EXPERIMENTAL
Intervention: Ultrafiltration on top of standard therapy (diuretics, cardiotonic, vasodilator) with furosemide (40 mg) given immediately and 24 hours after ultrafiltration.
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard treatment plan (diuretics, cardiotonic, vasodilator) without ultrafiltration.
Number of subjects: 146
Study: 35704616

Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 242
Study: 32954994

Group type: EXPERIMENTAL
Intervention: Positive perceptions of procedural justice
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Victim alcohol consumption
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Rape myth acceptance
Number of subjects: 571

Group type: COMPARATOR
Intervention: Victim race
Number of subjects: 571

Group type: COMPARATOR
Intervention: Participant sex
Number of subjects: 571
Study: 32224333

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham attention tasks (Control)
Number of subjects: 24
Study: 36096354

Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometry
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Icare rebound tonometry
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Pneumatonometry
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Rebound tonometry
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Pneumotonometry
Number of subjects: 135
Study: 35038956

Group type: EXPERIMENTAL
Intervention: Narrow-band intense pulsed light (DPL) treatment at a wavelength of 500-600 nm, initiated 2 weeks post-surgery, given 3 times over a 4-week period.
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (untreated half of the scar)
Number of subjects: 9
Study: 32505193

Group type: EXPERIMENTAL
Intervention: Exercise training alone
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Exercise training + high-protein diet
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (free diet, no exercise)
Number of subjects: 13
Study: 36355827

Group type: EXPERIMENTAL
Intervention: Iyengar yoga intervention self-administered over six weeks using an audio recording file
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care education (Control group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Iyengar yoga intervention
Number of subjects: 50
Study: 32544846

Group type: EXPERIMENTAL
Intervention: High fructose meal challenge
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: High glucose meal challenge
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Average glucose meal challenge
Number of subjects: 46
Study: 33871234

Group type: EXPERIMENTAL
Intervention: CRT (Chains Resistance Training)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TRT (Traditional Resistance Training)
Number of subjects: 30

Group type: COMPARATOR
Intervention: CG (Control Group)
Number of subjects: 30
Study: 33992718

Group type: EXPERIMENTAL
Intervention: CF-WBI (50 Gray [Gy]/25 fractions plus boost)
Number of subjects: 287

Group type: COMPARATOR
Intervention: HF-WBI (42.56 Gy/16 fractions plus boost)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: CF-WBI and HF-WBI
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: CF-WBI
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: HF-WBI
Number of subjects: 287
Study: 32487944

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure Intervention Trial (subset of patients with CKD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood Pressure in Dialysis Trial (pilot study)
Number of subjects: 0
Study: 35589026

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention using data-driven methods and training in interactive workshops
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention
Number of subjects: 0
Study: 33737437

Group type: EXPERIMENTAL
Intervention: upfront autologous HSCT
Number of subjects: 120

Group type: COMPARATOR
Intervention: immunosuppressive therapy (intravenous cyclophosphamide pulse therapy followed by mycophenolate mofetil) with rescue HSCT in case of treatment failure
Number of subjects: 120
Study: 32989958

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen and aromatase inhibitors
Number of subjects: 0
Study: 35802065

Group type: EXPERIMENTAL
Intervention: Prehabilitation intervention
Number of subjects: 118

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 118
Study: 32471423

Group type: EXPERIMENTAL
Intervention: Once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg via Ellipta inhaler
Number of subjects: 720

Group type: COMPARATOR
Intervention: Twice-daily budesonide/formoterol (BUD/FOR) 400/12 μg via metered-dose inhaler plus once-daily tiotropium (TIO) 18 μg via HandiHaler
Number of subjects: 720

Group type: COMPARATOR
Intervention: Twice-daily budesonide/formoterol (BUD/FOR) 400/12 μg plus once-daily tiotropium (TIO) 18 μg via HandiHaler
Number of subjects: 720
Study: 616734690

Group type: EXPERIMENTAL
Intervention: Intimate partner victimization
Number of subjects: 1233

Group type: EXPERIMENTAL
Intervention: Health risk behaviors
Number of subjects: 1233
Study: 34838606

Group type: EXPERIMENTAL
Intervention: Paroxetine treatment for 2 weeks
Number of subjects: 474
Study: 33354757

Group type: EXPERIMENTAL
Intervention: Men dissatisfied with their sex life
Number of subjects: 6048

Group type: EXPERIMENTAL
Intervention: Men reporting having had less sex than they would have liked
Number of subjects: 6048

Group type: EXPERIMENTAL
Intervention: Men who have looked for or met sex partners online
Number of subjects: 6048

Group type: EXPERIMENTAL
Intervention: Frequent pornography users
Number of subjects: 6048
Study: 33658645

Group type: EXPERIMENTAL
Intervention: R-DHAOx (oxaliplatin)
Number of subjects: 298

Group type: COMPARATOR
Intervention: R-DHACis (cisplatin) or R-DHACa (carboplatin)
Number of subjects: 298
Study: 33060088

Group type: EXPERIMENTAL
Intervention: Ghost ileostomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional loop ileostomy
Number of subjects: 60
Study: 32475229

Group type: EXPERIMENTAL
Intervention: Two needles arthrocentesis (TNA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Double-needle cannula arthrocentesis (DNCA)
Number of subjects: 20
Study: 34734811

Group type: EXPERIMENTAL
Intervention: Complete revascularization during primary PCI (PPCI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Complete revascularization during the same hospital admission
Number of subjects: 100
Study: 35822553

Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg once per day for 6 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 33045224

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg once daily (15 mg for creatinine clearance <50 mL/min)
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Dose-adjusted warfarin (target INR 2.0-3.0)
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1005
Study: 35449839

Group type: EXPERIMENTAL
Intervention: Low-frequency nerve therapy device
Number of subjects: 140

Group type: COMPARATOR
Intervention: Traditional treatment methods (Control)
Number of subjects: 140
Study: 33059519

Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS) for four weeks (20 min/3 days/week)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no EMS intervention)
Number of subjects: 32
Study: 32471397

Group type: EXPERIMENTAL
Intervention: Child Restraint Systems (CRS) use among children aged 0-5
Number of subjects: 9858

Group type: EXPERIMENTAL
Intervention: Child Restraint Systems (CRS) use among children aged 6-11
Number of subjects: 9858

Group type: COMPARATOR
Intervention: Sitting in the front row for children aged 0-11
Number of subjects: 9858

Group type: EXPERIMENTAL
Intervention: Sitting in the rear row with CRS use for children aged 0-11
Number of subjects: 9858

Group type: EXPERIMENTAL
Intervention: Seat belt use among children aged 12-17
Number of subjects: 9858
Study: 35460702

Group type: EXPERIMENTAL
Intervention: NIV‐NAVA
Number of subjects: 78

Group type: COMPARATOR
Intervention: NCPAP
Number of subjects: 78
Study: 33728932

Group type: EXPERIMENTAL
Intervention: Low HDL-C
Number of subjects: 4199

Group type: EXPERIMENTAL
Intervention: Metabolic dyslipidemia
Number of subjects: 4199
Study: 32703188

Group type: EXPERIMENTAL
Intervention: Detection dogs trained to identify SARS-CoV-2 infected samples
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (non-infected samples)
Number of subjects: 8
Study: 35575280

Group type: EXPERIMENTAL
Intervention: Prepare to Care intervention
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 38
Study: 32122870

Group type: EXPERIMENTAL
Intervention: Aceclofenac 100 mg tablet b.i.d and enzyme supplements 250 mg b.i.d for 6 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aceclofenac 100 mg tablet b.i.d
Number of subjects: 40
Study: 35304704

Group type: EXPERIMENTAL
Intervention: Iron deficiency defined as soluble transferrin receptor (sTfR) > 28.1 nmol/L
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Iron deficiency defined as ferritin < 45 µg/L
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Iron deficiency defined as ferritin < 30 µg/L
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Iron deficiency defined as sTfR-ferritin index > 1.5
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Incidence rate (IR) of iron deficiency per 100 person-years
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Incidence rate (IR) for ferritin < 45 µg/L
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Incidence rate (IR) for ferritin < 30 µg/L
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Incidence rate (IR) for sTfR-ferritin index > 1.5
Number of subjects: 2157
Study: 33442660

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry-3 surrogate classifier
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: St. Gallen surrogate classifier
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Prolif surrogate classifier
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: PAM50 subtyping
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment benefit
Number of subjects: 798
Study: 32282418

Group type: EXPERIMENTAL
Intervention: BUP‐XR (300 mg initial injection, followed by monthly doses of 300 mg or 100 mg)
Number of subjects: 669
Study: 35276451

Group type: EXPERIMENTAL
Intervention: Supervised task-oriented circuit training (TOCT) followed by a home-based task-oriented program
Number of subjects: 36
Study: 33323434

Group type: EXPERIMENTAL
Intervention: Routine measurement and reporting of EuroQoL 5‐Dimension 5‐Level (EQ‐5D‐5L) HRQOL data using an electronic platform
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Completion of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), 10-point Pain Rating Scale, and structured questionnaire
Number of subjects: 0
Study: 36411585

Group type: EXPERIMENTAL
Intervention: Linked Colour Imaging (LCI)
Number of subjects: 1828

Group type: COMPARATOR
Intervention: White Light Imaging (WLI)
Number of subjects: 1828
Study: 32434372

Group type: EXPERIMENTAL
Intervention: 1-month low-calorie diet (LCD)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Ordinary diet (control)
Number of subjects: 96
Study: 35510087

Group type: EXPERIMENTAL
Intervention: Clozapine (up to 400 mg per day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 33774680

Group type: EXPERIMENTAL
Intervention: Intermittent bright light during work (N=14)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Indoor light (Control group, N=15)
Number of subjects: 29
Study: 32270440

Group type: EXPERIMENTAL
Intervention: Imeglimin (IMEG) 1500 mg twice daily with Metformin (MET) 850 mg twice daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Imeglimin (IMEG) 1500 mg twice daily with Sitagliptin (SITA) 100 mg once daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Metformin (MET) 850 mg twice daily with placebo
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sitagliptin (SITA) 100 mg once daily with placebo
Number of subjects: 32
Study: 35778856

Group type: EXPERIMENTAL
Intervention: Non-nucleoside reverse transcriptase inhibitor (NNRTI)
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Protease inhibitor
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Stavudine
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Hepatitis C
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Higher baseline CD4 count
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: ART initiation
Number of subjects: 2614
Study: 35782072

Group type: EXPERIMENTAL
Intervention: Bronchial artery chemoembolization (BACE) combined with 125I seed implantation
Number of subjects: 102

Group type: COMPARATOR
Intervention: 125I seed implantation
Number of subjects: 102
Study: 34152584

Group type: EXPERIMENTAL
Intervention: Rituximab biosimilar PF-05280586 (RTX-PF)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Reference rituximab sourced from the EU (RTX-EU)
Number of subjects: 394
Study: 33028147

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Levcromakalim
Number of subjects: 15

Group type: COMPARATOR
Intervention: Glibenclamide with Levcromakalim
Number of subjects: 15
Study: 35470909

Group type: EXPERIMENTAL
Intervention: Oral vitamin D3, 600,000 IU 5 days before surgery (Group B)
Number of subjects: 196

Group type: COMPARATOR
Intervention: General standard of care (Group A)
Number of subjects: 196
Study: 33982986

Group type: EXPERIMENTAL
Intervention: LMA® Gastro™ airway
Number of subjects: 103

Group type: COMPARATOR
Intervention: gastrolaryngeal tube (GLT)
Number of subjects: 103
Study: 32861830

Group type: EXPERIMENTAL
Intervention: Educational film on chronic viral hepatitis (CVH)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Pre-intervention questionnaire
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Post-intervention questionnaire
Number of subjects: 219
Study: 35314325

Group type: EXPERIMENTAL
Intervention: Glassia (60 mg/kg body weight, weekly intravenous administration)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Prolastin (control group)
Number of subjects: 50
Study: 33179323

Group type: EXPERIMENTAL
Intervention: Fremanezumab quarterly (675 mg at baseline)
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Fremanezumab monthly (675 mg at baseline; 225 mg at Weeks 4 and 8)
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1088
Study: 35677368

Group type: EXPERIMENTAL
Intervention: Squill-Oxymel
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 32273630

Group type: EXPERIMENTAL
Intervention: Abound (24 g) administered for 14 days through an enteral feeding tube
Number of subjects: 10

Group type: COMPARATOR
Intervention: Historical control group (20 patients)
Number of subjects: 10
Study: 34555204

Group type: EXPERIMENTAL
Intervention: ATB‐346
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 0
Study: 32583478

Group type: EXPERIMENTAL
Intervention: Integrative Cognitive‐Affective Therapy (ICAT‐BED)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Cognitive‐Behavioral Guided Self‐Help (CBTgsh)
Number of subjects: 112
Study: 36434858

Group type: EXPERIMENTAL
Intervention: SBP 100-129
Number of subjects: 103

Group type: COMPARATOR
Intervention: SBP 130-160
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: SBP 100-129 with BBB disruption
Number of subjects: 103

Group type: COMPARATOR
Intervention: SBP 130-160 with BBB disruption
Number of subjects: 103
Study: 32896932

Group type: EXPERIMENTAL
Intervention: QS-755 nm
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: QS-532 nm
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: PS-755 nm
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Overall treatment satisfaction
Number of subjects: 41
Study: 32503867

Group type: EXPERIMENTAL
Intervention: Smartphone-based digital stewardship applications (apps) with local guideline directed empirical antimicrobial use by physicians
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Smartphone-based digital stewardship applications (apps)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Use of the app by everyone after the intervention period
Number of subjects: 540
Study: 35098531

Group type: COMPARATOR
Intervention: Intravenous (i.v.) N-acetylcysteine (NAC) in healthy volunteers with contrast
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intravenous (i.v.) NAC in healthy volunteers without contrast
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intravenous (i.v.) NAC in patients with CKD3 receiving contrast
Number of subjects: 66

Group type: COMPARATOR
Intervention: Oral NAC in healthy volunteers
Number of subjects: 66

Group type: COMPARATOR
Intervention: Oral NAC in patients with CKD3
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intravenous (i.v.) NAC in patients with CKD3 without contrast
Number of subjects: 66
Study: 33004272

Group type: EXPERIMENTAL
Intervention: FOLFOX
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: CAPOX
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Oxaliplatin treatment < 2 months prior to EVA/PCD analysis
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 5-FU
Number of subjects: 87

Group type: COMPARATOR
Intervention: Mitomycin and Irinotecan
Number of subjects: 87
Study: 33974993

Group type: EXPERIMENTAL
Intervention: LCS restriction (replacement of diet beverages with still or sparkling water and avoidance of other sources of LCSs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual LCS intake (control)
Number of subjects: 0
Study: 33415870

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Herbal cake separated moxibustion group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine rehabilitation group
Number of subjects: 90
Study: 36235821

Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverage (SSB) consumption with glucose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverage (SSB) consumption with fructose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverage (SSB) consumption with sucrose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no SSB consumption)
Number of subjects: 0
Study: 33624527

Group type: EXPERIMENTAL
Intervention: taVNS
Number of subjects: 36

Group type: COMPARATOR
Intervention: sham-ES
Number of subjects: 36
Study: 35511720

Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula (HFNC) at 60L/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula (HFNC) at 40L/min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP) at 4cmH2O
Number of subjects: 10
Study: 33938977

Group type: EXPERIMENTAL
Intervention: Three-piece, inflatable penile prosthesis in radial-free-flap phalloplasty
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Penile prosthesis design for use in phalloplasties
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Transmen-specific penile prosthesis
Number of subjects: 400
Study: 32781397

Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch‐up (ABC) intervention
Number of subjects: 103

Group type: COMPARATOR
Intervention: Developmental Education for Families (DEF) control intervention
Number of subjects: 103
Study: 36084050

Group type: EXPERIMENTAL
Intervention: PrEP use
Number of subjects: 2086
Study: 34640836

Group type: EXPERIMENTAL
Intervention: Magnetic Tape®
Number of subjects: 22

Group type: COMPARATOR
Intervention: Kinesio tape
Number of subjects: 22
Study: 32584519

Group type: EXPERIMENTAL
Intervention: Transfusion reaction learning module plus standard rotation training
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no module) receiving only standard training
Number of subjects: 55
Study: 35287002

Group type: EXPERIMENTAL
Intervention: Unfolding case-based learning
Number of subjects: 115

Group type: COMPARATOR
Intervention: Traditional learning methods
Number of subjects: 115
Study: 33809557

Group type: EXPERIMENTAL
Intervention: Topically applied formulation containing components of natural moisturizing factor (NMF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo formulation
Number of subjects: 12
Study: 32546652

Group type: EXPERIMENTAL
Intervention: Combined forecasts of neurology experts for the stroke trial
Number of subjects: 71

Group type: COMPARATOR
Intervention: Noncommittal prediction algorithm for the stroke trial
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Combined forecasts of neurology experts for the MS study
Number of subjects: 71

Group type: COMPARATOR
Intervention: Noncommittal prediction algorithm for the MS study
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Combined forecasts of neurology experts for the ALS study
Number of subjects: 71

Group type: COMPARATOR
Intervention: Noncommittal prediction algorithm for the ALS study
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Individual predictions by experts
Number of subjects: 71
Study: 34278540

Group type: EXPERIMENTAL
Intervention: ESAS‐r: Renal
Number of subjects: 506

Group type: COMPARATOR
Intervention: EQ‐5D‐5L
Number of subjects: 506
Study: 33493423

Group type: EXPERIMENTAL
Intervention: Combination of an inhaled corticosteroid and a β‐agonist
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 32896919

Group type: EXPERIMENTAL
Intervention: Subcutaneous ICD (S-ICD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transvenous ICD
Number of subjects: 0